Citigroup
MRKR icon

Citigroup’s Marker Therapeutics MRKR Stock Holding History

Citigroup’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$9 – 6222
2025
Q4 		$9 Sell
6
-9,270
-100% -$10.5K ﹤0.01% 5820
2025
Q3 		$8.28K Buy
+9,276
New +$11.5K ﹤0.01% 5080
2022
Q2 		– Sell
-70
Closed – – 6499
2022
Q1 		$0 Buy
+70
New +$400 ﹤0.01% 6508
2021
Q3 		– Sell
-7
Closed – – 6104
2021
Q2 		$0 Sell
7
-235
-97% -$6.19K ﹤0.01% 6300
2021
Q1 		$5K Sell
242
-310
-56% -$7.09K ﹤0.01% 5895
2020
Q4 		$8K Buy
552
+410
+289% +$6.37K ﹤0.01% 7012
2020
Q3 		$2K Sell
142
-237
-63% -$4.32K ﹤0.01% 7307
2020
Q2 		$8K Sell
379
-389
-51% -$8.51K ﹤0.01% 7136
2020
Q1 		$15K Buy
768
+225
+41% +$5.73K ﹤0.01% 6859
2019
Q4 		$16K Buy
543
+409
+305% +$14.9K ﹤0.01% 7023
2019
Q3 		$6K Sell
134
-625
-82% -$36.9K ﹤0.01% 7280
2019
Q2 		$60K Sell
759
-3,895
-84% -$231K ﹤0.01% 6307
2019
Q1 		$307K Buy
+4,654
New +$272K ﹤0.01% 4683

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citigroup's MRKR Position: Q1 2026 in Review

Citigroup sold out of Marker Therapeutics (MRKR) in Q1 2026, closing a stake of 6 shares — an estimated $9 sold.

Citigroup first reported a position in MRKR in Q1 2019 and held it in 13 quarters. The position peaked at $307K in Q1 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • Citigroup reported no remaining Marker Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 6 Marker Therapeutics shares in Q1 2026, an estimated $9.
  • Citigroup first reported a position in Marker Therapeutics in Q1 2019 and held it in 13 quarters.
  • Citigroup's Marker Therapeutics position peaked at $307K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.